Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple MyelomaStatus: open
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
Treatment for Solid Tumors, Lymphomas, or Multiple Myeloma
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
SponsorsThis trial is sponsored by National Cancer Institute (NCI).
Interested in Clinical Trial?
Providers Associated With This Trial
- Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Chief of Gynecologic Oncology Service; Associate Director for Clinical Research, Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology
- Jennifer M. Scalici, M.D.Gynecologic OncologistAssociate Professor of Interdisciplinary Clinical Oncology
- Michael A. Finan, M.D., F.A.C.S., F.A.C.O.GGynecologic OncologistProfessor of Interdisciplinary Clinical Oncology
- Daniel G. Cameron, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology
- Thomas W. Butler, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Oncology
- David R. Clarkson, M.D.Medical Oncologist and HematologistProfessor of Interdisciplinary Clinical Oncology; Fellowship Program Director